FIELD: medicine; ophthalmology.
SUBSTANCE: invention can be used in treating pharmacoresistant forms of infectious keratitis of bacterial, fungal or acanthamoeba origin. That is ensured by fulguration and crosslinking of the corneal tissue infiltration zone. Fulguration is carried out with a spark plasma discharge generated by direct current with output power of 1.6 Wt. Cross-linking is carried out by installations of 20 % dextran solution every 2 minutes for 20 minutes and UV-irradiation of the central corneal zone with diameter of 8 mm for 10 minutes with radiation intensity 9 mW/cm2.
EFFECT: invention provides effective treatment of pharmacoresistant forms of infectious keratitis, having bacterial, fungal, acanthamoeba origin, due to treatment of corneal surface with areas of small area, as a result, healthy tissue surrounding the treated area is not damaged.
1 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING ACANTHAMOEBA KERATITIS COMPLICATED BY A SECONDARY INFECTION | 2019 |
|
RU2716756C1 |
METHOD OF TREATING SEPTIC FUSION ULCERS OF CORNEA IN DOGS AND CATS BY ACCELERATED ULTRAVIOLET CROSS-LINKING | 2020 |
|
RU2739797C1 |
METHOD FOR PURULENT CORNEAL ULCERS TREATMENT | 2016 |
|
RU2635454C1 |
METHOD OF SURGICAL TREATMENT OF CORNEAL ULCER OF VARIOUS ETIOLOGY | 2017 |
|
RU2652078C1 |
METHOD OF TREATING HERPETIC KERATITIS | 2013 |
|
RU2531426C1 |
METHOD OF TREATING COMPLICATIONS OF VIRAL AND BACTERIAL KERATOCONJUNCTIVITIS IN ANIMALS BY MEANS OF COLLAGEN CROSS-LINKING | 2018 |
|
RU2707792C1 |
METHOD FOR CORNEAL COLLAGEN CROSSLINKING IN KERATECTASIAS OF VARIOUS GENESIS | 2021 |
|
RU2778968C1 |
OPHTHALMIC COMPOSITION OF EYE DROPS FOR TREATING ANTIBIOTIC-RESISTANT INFECTIOUS-INFLAMMATORY EYE DISEASES | 2014 |
|
RU2561048C1 |
METHOD OF TREATING INFECTIOUS INFLAMMATORY DISEASES OF CORNEA | 2010 |
|
RU2434607C1 |
METHOD FOR ULTRAVIOLET CORNEAL CROSS-LINKING TAKING INTO ACCOUNT TOPOGRAPHIC PACHYMETRY AND KERATOTOPOGRAPHY IN PATIENTS WITH A THIN CORNEA | 2020 |
|
RU2735377C1 |
Authors
Dates
2024-05-06—Published
2023-06-06—Filed